Applicant, as named in the Orange Book

Vanda Pharms Inc

Vanda Pharmaceuticals Inc · Nasdaq: VNDA

Company and ticker: cliffwatch mapping, checked against SEC EDGAR · SEC filings

Next listed expiry: Fanapt on 28 Dec 2031. 6 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	Earliest generic entry	Basis
Fanapt NDA 022192 · 7 strengths iloperidone	iloperidone	28 Dec 2031 patent, carve-out possible	patent, carve-out possible
Nereus NDA 220152 tradipitant	tradipitant	9 Aug 2036 patent, carve-out possible	patent, carve-out possible
Hetlioz NDA 205677 tasimelteon	tasimelteon	21 Feb 2041 patent, carve-out possible	patent, carve-out possible
Hetlioz Lq NDA 214517 tasimelteon	tasimelteon	21 Feb 2041 patent, carve-out possible	patent, carve-out possible
Bysanti NDA 220358 · 7 strengths milsaperidone	milsaperidone	31 May 2044 patent, carve-out possible	patent, carve-out possible
Ponvory NDA 213498 · 2 strengths ponesimod	ponesimod	24 Dec 2044 patent, carve-out possible	patent, carve-out possible

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.